HUTCHMED Doses First Patient in Global Phase I Trial of HMPL-A830 KRAS-EGFR ATTC

summarizeSummary

HUTCHMED dosed the first patient in its global Phase I trial of HMPL-A830, a first-in-class KRAS-EGFR antibody conjugate, advancing the ATTC platform into the clinic.

check_boxKey Events · Product Development and Regulatory · HCM

• First Patient Dosed in Phase I

  First patient received first dose of HMPL-A830 in China on September 24, 2026, initiating the Phase Ia dose escalation part of the global trial.

• Novel KRAS-EGFR ATTC Mechanism

  HMPL-A830 combines a KRAS small molecule inhibitor payload with an anti-EGFR antibody, designed to deliver dual KRAS and EGFR inhibition directly to EGFR-expressing tumors.

• Trial Design and Scope

  Phase Ia will determine maximum tolerated dose and recommended dose for expansion in patients with unresectable, advanced or metastatic solid tumors; ClinicalTrials.gov identifier NCT07718581.

• GSK Partnership Context

  Follows the September 3, 2026 exclusive worldwide license agreement with GSK (ex-Greater China); HUTCHMED is responsible for the global Phase I program.

auto_awesomeAnalysis · HCM · Life Sciences

HUTCHMED has initiated the Phase Ia portion of a global clinical trial for HMPL-A830, its first-in-class KRAS-EGFR antibody-targeted therapy conjugate, with the first patient dosed in China on September 24, 2026. This marks the first clinical validation of the ATTC platform and follows the September 3, 2026 exclusive worldwide licensing deal with GSK. The trial will evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with unresectable, advanced or metastatic solid tumors. While early-stage, this is a meaningful milestone for a novel modality targeting KRAS-altered tumors — a high-unmet-need area where HUTCHMED's dual EGFR/KRAS inhibition approach could differentiate from existing therapies.